Skip to main content

Table 2 The dose-volume parameters of accumulated dose

From: Adaptive planning based on single beam optimization in passive scattering carbon ion radiotherapy for patients with pancreatic cancer

Volume

Parameter

AP-1

AP-2

TM

BM

Original plan

CTV1

V95 (%)

99.4 (95.6–99.9)

97.5(94.3–99.4)

88.3 (79.4–97.5)*

84.8 (67.7–96.7)*

99.5 (93.0–99.9)

 

V90 (%)

99.9 (99.1–100)

99.5 (98.7–100)

94.7 (89.1–99.7)*

91.2 (76.4–99.4)*

100 (97.8–100)

 

D98 [Gy (RBE)]

40.1(38.4–40.8)

39.1 (37.9–40.3)

35.5 (32.1–39.1)*

33.0 (22.8–38.8)*

40.2 (37.1–40.7)

 

Mean [Gy (RBE)]

41.4 (41.1–42.0)

41.3 (41.1–41.5)

40.9 (40.2–41.2)*

40.6 (38.5–41.1)*

41.4 (41.1–41.7)

CTV2

V95 (%)

96.7 (85.1–99.8)

91.8 (82.5–98.4)*

85.1 (81.0–98.3)*

80.5 (37.1–95.1)*

93.5 (86.1–100)

 

V90 (%)

99.0 (91.1–100)

96.6 (88.5–99.8)

94.4 (89.9–99.6)

89.4 (46.5–98.3)*

98.5 (91.3–100)

 

D98 [Gy (RBE)]

51.2 (43.8–54.5)

48.3 (44.4–52.8)

46.3 (43.4–52.8)

44.7 (21.6–50.0)*

49.3 (43.3–54.6)

 

Mean [Gy (RBE)]

55.0 (54.3–55.4)

54.7 (54.0–55.2)*

54.4 (53.9–55.2)*

53.8 (44.6–54.9)*

54.8 (54.3–55.3)

GTV

V95 (%)

99.0 (88.2–100)

97.3 (90.7–100)

94.9 (85.8–100)

90.5 (44.4–100)*

98.5 (85.6–100)

 

V90 (%)

99.8 (93.5–100)

99.6 (96.4–100)

99.0 (94.5–100)

96.7 (53.5–100)*

99.6 (90.9–100)

 

D98 [Gy (RBE)]

53.6 (45.5–55.3)

52.1 (47.8–55.0)

50.8 (47.6–55.1)

48.0 (28.4–54.9)*

52.3 (43.3–55.1)

 

Mean [Gy (RBE)]

55.2 (54.8–55.6)

55.1 (54.5–55.5)

55.0 (54.3–55.4)

54.6 (47.3–55.4)*

55.1 (54.3–55.5)

Duodenum

D2cc [Gy (RBE)]

28.5 (18.5–36.3)

32.1 (22.2–49.8)*

27.2 (20.8–47.4)

31.1 (18.2–46.9)

25.2 (21.3–40.2)

 

V10 [Gy (RBE)] (ml)

36.8 (21.8–79.5)

37.1 (22.5–82.5)

40.7 (24.3–79.0)

38.2 (27.7–81.0)

41.2 (22.5–82.7)

 

V20 [Gy (RBE)] (ml)

7.0 (1.7–25.6)

11.0 (3.1–52.2)*

5.6 (2.1–29.6)*

7.2 (0.9–25.5)*

3.5 (2.3–20.1)

 

V30 [Gy (RBE)] (ml)

1.4 (0.5–10.6)

2.9 (0.2–19.7)

1.9 (0.3–13.2)

2.5 (0.0–10.3)

1.0 (0.4–9.5)

 

Mean [Gy (RBE)]

11.4 (6.8–15.1)

12.8 (7.8–22.4)

10.7 (7.8–20.5)

11.6 (7.8–19.2)

10.1 (7.7–15.6)

Stomach

D2cc [Gy (RBE)]

35.2 (19.0–40.1)

38.4 (23.7–42.3)

34.0 (18.9–38.4)

35.3 (21.1–44.0)

36.0 (16.9–43.6)

 

V10 [Gy (RBE)] (ml)

73.4 (23.3–106.1)

73.9 (26.1–106.3)

71.3 (17.2–107.6)

65.4 (19.2–100.1)

82.5 (20.9–113.8)

 

V20 [Gy (RBE)] (ml)

14.2 (1.7–45.2)

20.3 (3.8–48.9)

17.4 (1.6–49.7)

20.8 (2.4–45.4)

15.7 (1.1–51.2)

 

V30 [Gy (RBE)] (ml)

4.7 (0.2–18.0)

6.6 (0.6–21.6)

5.4 (0.1–22.3)

5.1 (0.3–20.7)

6.3 (0.1–26.9)

 

Mean [Gy (RBE)]

7.6 (3.5–16.9)

7.6 (3.9–17.8)

7.3 (2.8–17.7)

6.8 (3.2–16.6)

8.9 (2.9–18.9)

  1. Data are presented as median (range)
  2. TM tumor matching, BM bone matching, CTV clinical target volume, GTV gross tumor volume, V95 and V90 the percentage of the volume receiving 95% and 90% of prescribed dose, D98 the dose coverage 98% of the volume. Vn the absolute volume receiving n Gy (RBE)
  3. *P < 0.05 compared with original plan